Jennison Associates
PRNB

Jennison Associates’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Jennison Associates’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-433,306
Closed -$25.7M – 725
2020
Q1 		$25.7M Buy
433,306
+111,018
+34% +$6.47M 0.03% 221
2019
Q4 		$17.7M Buy
+322,288
New +$12M 0.02% 329

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates's PRNB Position: Q2 2020 in Review

Jennison Associates sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q2 2020, closing a stake of 433,306 shares — an estimated $25.7M sold.

Jennison Associates first reported a position in PRNB in Q4 2019 and held it in 2 quarters. The position peaked at $25.7M in Q1 2020. 137 funds tracked by Wall St. Rank hold PRNB as of Q2 2020.

  • Jennison Associates reported no remaining Principia Biopharma Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Jennison Associates sold 433,306 Principia Biopharma Inc. Common Stock shares in Q2 2020, an estimated $25.7M.
  • Jennison Associates first reported a position in Principia Biopharma Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • Jennison Associates's Principia Biopharma Inc. Common Stock position peaked at $25.7M in Q1 2020.
  • 137 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q2 2020.

Based on Jennison Associates's 13F filing for Q2 2020, filed 6 Aug 2020.